Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Ann
23 Aprile 2008 - 4:00PM
PR Newswire (US)
EAST SETAUKET, N.Y., April 23 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings (OTC:LIXT) (BULLETIN BOARD: LIXT) announced
today that Dr. Jie Lu and Dr. Zhengping Zhuang of the Surgical
Neurology Branch (SNB), National Institute of Neurological
Disorders and Stroke (NINDS), National Institutes of Health (NIH)
and its collaborator, Lixte Biotechnology Holdings. Inc., reported
at the Annual Meeting of the American Association of Cancer
Research that its lead compound LB-1, one of a patent-pending
proprietary series of agents, has anti-cancer activity against
human glioblastoma multiforme cells in a mouse model of cancer.
Glioblastoma multiforme is the most common and aggressive brain
tumor of adults. The Dr. John S. Kovach, President and CEO of
Lixte, said that the company and SNB, NINDS are continuing to
develop LB-1 and analogs of the compound for the treatment of human
brain cancers. Brain cancers pose a particular challenge to the
development of effective drug treatments. The brain is protected by
a physiological barrier that prevents the entry of many compounds
from the blood into brain tissue. To be effective, drugs must be
designed either to pass this barrier or be administered directly
into the brain. "We are pursuing both strategies for the treatment
of glioblastoma multiforme in a rat model in which the cancer is
growing in the brain," said Dr. Kovach. "We want to be certain that
we achieve drug delivery into the brain at concentrations that
inhibit these tumors." About Lixte Biotechnology Holdings, Inc.:
Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and
diagnostics company. Founded as a biomarker-diagnostics company in
2005, Lixte develops new chemotherapy drugs targeting molecular
abnormalities of common human cancers. About the National Institute
of Neurological Disorders and Stroke (NINDS), (NIH): NINDS
(http://www.ninds.nih.gov/) is a component of the National
Institutes of Health (NIH), and is the nation's primary supporter
of biomedical research on the brain and nervous system. The
National Institutes of Health (NIH) - The Nation's Medical Research
Agency - includes 27 Institutes and Centers and is a component of
the U.S. Department of Health and Human Services. It is the primary
federal agency for conducting and supporting basic, clinical and
translational medical research, and it investigates the causes,
treatments, and cures for both common and rare diseases. For more
information about NIH and its programs, visit http://www.nih.gov/.
Forward-Looking Statements This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the condensed
consolidated financial statements and notes thereto included in
Item 1 of the Quarterly Report on Form 10-QSB for the quarter
ending September 30, 2007. For additional information Please see
our Website: http://www.lixte.com/ For Investor Information, please
contact: Frank Benedetto Mirador Consulting, Inc. 561-989-3600
DATASOURCE: Lixte Biotechnology Holdings CONTACT: Frank Benedetto,
Mirador Consulting, Inc., +1-561-989-3600 Web site:
http://www.lixte.com/ http://www.nih.gov/ http://www.ninds.nih.gov/
Copyright